Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Murray B. Stein, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00947570
First received: July 27, 2009
Last updated: December 27, 2012
Last verified: December 2012

July 27, 2009
December 27, 2012
October 2007
August 2012   (final data collection date for primary outcome measure)
Blood oxygen level dependent (BOLD) response in amygdala, insula, and medial prefrontal cortex, as measured with functional magnetic resonance imaging (fMRI) [ Time Frame: Measured at baseline and after 10 to 14 weeks of treatment ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00947570 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study)
Neural Substrates of Anticipation and Interoception in Anxiety Disorders

This study will examine the effects of cognitive behavioral therapy on brain function in people with anxiety disorders.

Anxiety disorders are characterized by excessive and irrational fears of common situations that impair normal functioning. Neuroimaging allows researchers to examine brain functioning as people are presented with tasks that provoke or model anxiety. Neuroimaging research suggests that anxiety is moderated by a neural circuit involving three parts of the brain: the amygdala, the insula, and the prefrontal cortex (PFC). Increased activation of the amygdala and insula is associated with high anxiety, although activation of the PFC is thought to reduce anxiety. Cognitive behavioral therapy (CBT) is the only type of psychotherapy with strong evidence for effectively treating panic disorder (PD) and generalized anxiety disorder (GAD), but it only works about half the time. This study will use neuroimaging to examine when and how CBT affects brain functioning in people with PD and GAD. The long-term goals of the research are to develop neuroimaging as a diagnostic tool, to use neuroimaging to predict treatment response, and to understand which changes in brain functioning are related to successful treatment.

Participation in this study will last approximately 3 months. Four groups of participants will be recruited: healthy controls and people with PD, GAD, or social phobia (SP). All participants will undergo functional magnetic resonance imaging (fMRI) scanning—a measure of brain functioning—at the first visit. During the fMRI scan, participants will be asked to perform computerized tasks that involve responding to images. This will be the only visit that the healthy controls and people with SP complete; their inclusion in the study establishes a comparison point for the brain scans of the other participants. People with PD and GAD will then be asked to complete 10 sessions of CBT over a 10- to 14-week period. After 3 months, these participants will again undergo fMRI scanning. At 3 and 6 months after the completion of CBT, these participants will be asked to complete follow-up questionnaires about their anxiety.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Anxiety Disorders
Behavioral: Cognitive behavioral therapy for anxiety
10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
Other Names:
  • CBT
  • Behavior Therapy
Experimental: Cognitive behavioral therapy
Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
Intervention: Behavioral: Cognitive behavioral therapy for anxiety
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • High school or higher education
  • DSM-IV diagnosis of panic disorder (with ongoing symptoms), generalized anxiety disorder, or both

Exclusion Criteria:

  • Lifetime diagnosis of psychotic disorder, organic mental disorder, or bipolar I disorder
  • Substance dependence within the last 12 months or diagnosis of alcohol or substance abuse within the past month
  • Use of psychotropic or anti-epileptic medications within the past 6 weeks
  • Heavy caffeine use, defined as drinking more than 6 caffeinated beverages per day
  • Current smoker
  • Possibility of pregnancy
  • History of claustrophobia or difficulty lying flat for long periods
  • Ferrous metal in the body

Exclusion Criteria for Healthy Controls only:

  • Lifetime diagnosis of major depressive disorder (MDD), bipolar I or II disorder, panic disorder (PD), agoraphobia without panic, generalized anxiety disorder (GAD), social phobia (SP), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), or an eating disorder
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00947570
R01 MH065413, R01MH065413, DATR A2-AIA
No
Murray B. Stein, University of California, San Diego
University of California, San Diego
National Institute of Mental Health (NIMH)
Principal Investigator: Murray B. Stein, MD, MPH University of California, San Diego
University of California, San Diego
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP